APL (Apotek Produktion & Laboratorier AB) is a Swedish state‑owned pharmaceutical manufacturer with a unique public policy assignment: to develop, produce, and supply pharmacy‑compounded medicines for patients with specific needs when commercial alternatives are unavailable. With production facilities in Stockholm, Malmö, Gothenburg, Strängnäs, and Umeå, APL also provides contract development and manufacturing (CDMO) services to the Life Science industry.
Sustainability is central to our operations
Fulfilling our public policy assignment is APL’s highest priority, ensuring access to essential medicines when registered products cannot meet patient needs. As a pharmaceutical manufacturer, we also hold a clear responsibility to minimize environmental impact while maintaining the highest standards of quality and patient safety. Recent investments include modernizing manufacturing lines, introducing 3D‑printing technology for individualized medicines within the ExtempoPrint concept, and advancing digitalization through electronic batch documentation. Together, these initiatives strengthen long‑term sustainability and reduce our overall environmental footprint.
